Management of autoimmune blistering illness can be difficult since treatment techniques vary widely and there is no one standard of care. In order to give the best management advice to physicians, researchers combined the recommendations of worldwide management standards. In November 2019, a systematic literature search in PubMed/MEDLINE for published blistering disease management recommendations and consensus statements was undertaken. Guidelines from reputable dermatologic associations and expert consensus committees were incorporated. They eliminated literature reviews, guidelines created by an organisation that did not include dermatologists, and guidelines that were unique to a single treatment. All guidelines were examined in all languages. They chose eleven guidelines from dermatologic organisations and consensus committees that met our inclusion requirements. In bullous pemphigoid, several variations in recommendations were discovered, most notably when to introduce adjuvants for refractory illness. In mucous membrane pemphigoid, systemic corticosteroids and immunosuppressants/biologics were used to treat the affected areas. 

Although there was no general agreement on the best first-line treatment for epidermolysis bullosa acquisita, a combination of immunosuppressive, anti-inflammatory, and anti-neutrophil therapy was used. A comparison of management recommendations found underrepresentation of guidelines from developing countries as well as significant variations in management practises between dermatologists from Europe and Asia. They ascribe these disparities to the passage of time between recommendations, geographical variations, and the needs of local healthcare systems.